Roadshow
V5 Lung AI
The software assists physicians in more accurately detecting nodules on low-dose CT (LDCT) images and reduces the time required for image interpretation.
It also provides detailed characteristics of the identified nodules, including diameter, volume, nodule type, and Lung-RADS score.
In addition, the system can automatically compare chest CT scans taken at different time points, locate the same nodule across studies, and analyze its growth over time by calculating the volume doubling time (VDT) as a reference for clinicians. After AI image analysis, the system can also generate a comprehensive report based on the ACR Lung-RADS and Fleischner Society guidelines.
- Established 2023
- Company V5med Inc.
- Telephone +886-3-623-3089 / +886-7-363-6510#23388
- Email Cooper.Yang@v5.com.tw
- Address 7F, No. 36, Chenggong 12th St., Zhubei City, Hsinchu County 302050, Taiwan (R.O.C.)
V5med Inc., a subsidiary of V5 Technologies, focuses on smart healthcare innovation. Its proprietary “V5 Lung AI” is the first low-dose CT pulmonary nodule detection software in Taiwan to receive both U.S. FDA 510(k) clearance and TFDA approval, with over 95% detection accuracy and strong clinical recognition.
Beyond lung cancer screening, V5med is expanding its AI portfolio to include AccuCardio for coronary artery calcification analysis and AccuPulmo for pulmonary fibrosis and emphysema detection—advancing early diagnosis in thoracic and cardiovascular diseases.
With strong R&D capabilities, V5med continues to drive innovation and apply cutting-edge semiconductor AI technologies to global healthcare, guided by its vision: “Leading a healthier future through technological innovation.”